Glenmark Life Sciences IPO Date, Review, Price, Form & Market Lot Details

Glenmark Life Sciences IPO to hit the market on 27 July 2021 as per the RHP filed on 19 July 2021. The company to raise ₹1514 crores via initial public offer with a face value of ₹2 per equity share. The IPO comprises fresh issue of 1060 crores and offer for sale of 6,300,000 equity shares of Glennmark Pharmceuticals Limited .

 

Glenmark Life Sciences IPO to hit the market on 27 July 2021 and closes on 29 July 2021. The company plans to raise ₹1514 crore through the initial public offerings. Glenmark Life Sciences is an API arm of Glenn Mark Pharma, a leading drug maker. They are one of the leading developer and manufacturer of Active Pharmaceutical Ingredients (APIs). They are making high-quality drugs by unlocking the possibilities of science. They created the strong relationship with leading pharmaceutical companies that have helped us expand our product offerings and geographic reach. They have 120 API in their catalogue. They supply their API to 540 pharma companies in India and overseas. They export their products in Europe, Latin America, North America, Japan, and the rest of the world. Check out Glenmark Life Sciences IPO details.

Important Details:

According to the DRHP, the proceeds from the IPO will be used for:

• Payment of outstanding purchase consideration to the promoter for the spin-off of the API businessb)
•  Funding capital expenditure requirements
• General corporate purposes

How to apply in Share Holder Quota:

If you want to apply Glenmark Life Sciences IPO in the share holder quota, you should buy at least 1 share of Glenmark Pharma. It should be in your demat account when the company announce their IPO date or before RHP.

Note: According to RHP there is no Share Holders Quota.

 

Equity Shares outstanding prior to the Issue = 10,78,04,950 Shares
Fresh Issue of 1,47,22,222 Shares Rs.720 = Rs.1,060.00 Crores
Offer for Sale of 63,00,000 Shares Rs.720 = Rs.453.60 Crores
Equity Shares outstanding after the Issue = 12,25,27,172 Shares

Category-wise Break up:
Anchor: 63,06,667 Shares = 454.08 Crores
QIB: 42,04,444 Shares = 302.72 Crores
NII: 31,53,333 Shares = 227.04 Crores
RII: 73,57,778 Shares = 529.76 Crores (Lot size: 20 = 3,67,889 Forms)
Total Issue: 2,10,22,222 Shares = 1513.60 Crores

Subscription Required for 1X
RII: 3,67,889 Forms
NII: 227.04 Crores

Financial Information (Basis of Valuation)

The information is collated from the following documents:
1) RHP = Red Herring Prospectus Dated July 19, 2021 (358 pages)

EPS for FY18-19 >>> Rs.24.64 (Page #82 of RHP)
EPS for FY19-20 >>> Rs.29.04 (Page #82 of RHP)
EPS for FY20-21 >>> Rs.32.61 (Page #82 of RHP)

RoNW for FY18-19 >>> 99.25% (Page #83 of RHP)
RoNW for FY19-20 >>> 77.94% (Page #83 of RHP)
RoNW for FY20-21 >>> 46.71% (Page #83 of RHP)

NAV as on March 31, 2021 was Rs.69.82 (Page #83 of RHP)

Listed Industry Peer Group:

• Divis Laboratories
• Laurus Labs
• Shilpa Medicare
• Aarti Drugs
• Solara Active Pharma Sciences

In This Article

The Glenmark Life Sciences IPO minimum market lot is 20 shares with ₹14,400 application amount. The retail investors can apply up-to 13 lots with 260 shares or ₹187,200 amount.

 

The Glenmark Life Sciences IPO date is 27 July 2021 and the IPO close date is 29 July 2021. The allotment date is 03 August 2021 and the IPO may list on 06 August 2021.

 

We are a leading developer and manufacturer of Active Pharmaceutical Ingredients (APIs)

We are in the business of making high-quality drugs by unlocking the possibilities of science. Over the years, we have established strong relationships with leading global generic pharmaceutical companies that have helped us expand our product offerings and geographic reach. We work with 16 of the 20 largest generic companies globally. (Source: A Year of Surprises Shakes Up Off-Patent Industry” | Informa, 2020)

With 120 APIs in our catalogue, we are blending innovation and operational excellence to deliver on the promise of service, reliability, and consistent product quality.

Powered by our massive, world-class manufacturing and research capabilities, we supply high-quality APIs to more than 540 pharma companies in multiple countries.

Note: Check Glenmark Life Sciences IPO allotment status on KFintech website allotment URL. Click Here